Bin Chen

Dr. Bin Chen


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
XYXue Yang
Xue Yang
PPPratheeba Palasuberniam
Pratheeba Palasuberniam
DKDaniel Kraus
Daniel Kraus
BCBin Chen
Bin Chen
Aminolevulinic acid (ALA) is the first metabolite in the heme biosynthesis pathway in humans. In addition to the end product heme, this pathway also produces other porphyrin metabolites. Protoporphyrin (PpIX) is one heme precursor porphyrin with good fluorescence and photosensitizing activity. Because tumors and other proliferating cells tend to exhibit a higher level of PpIX than normal cells after ALA incubation, ALA has been used as a prodrug to enable PpIX fluorescence detection and photodynamic therapy (PDT) of lesion tissues. Extensive studies have been carried out in the past twenty years to explore why some tumors exhibit elevated ALA-mediated PpIX and how to enhance PpIX levels to achieve better tumor detection and treatment. Here we would like to summarize previous research in order to stimulate future studies on these important topics. In this review, we focus on summarizing tumor-associated alterations in heme biosynthesis enzymes, mitochondrial functions and porphyrin transporters that contribute to ALA-PpIX increase in tumors. Mechanism-based therapeutic strategies for enhancing ALA-based modalities including iron chelators, differentiation agents and PpIX transporter inhibitors are also discussed.

18 August 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PPPratheeba Palasuberniam
Pratheeba Palasuberniam
XYXue Yang
Xue Yang
DKDaniel Kraus
Daniel Kraus
PJPatrick Jones
Patrick Jones
KMKenneth A. Myers
Kenneth A. Myers
BCBin Chen
Bin Chen
Photosensitizer protoporphyrin IX (PpIX) fluorescence, intracellular localization and cell response to photodynamic therapy (PDT) were analyzed in MCF10A normal breast epithelial cells and a panel of human breast cancer cells including estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) positive and triple negative breast cancer (TNBC) cells after treatment with PpIX precursor aminolevulinic acid (ALA). Although PpIX fluorescence was heterogeneous in different cells, TNBC cells showed significantly lower PpIX level than MCF10A and ER- or HER2-positive cells. PpIX fluorescence in TNBC cells also had much less mitochondrial localization than other cells. There was an inverse correlation between PpIX fluorescence and cell viability after PDT. Breast cancer cells with the highest PpIX fluorescence were the most sensitive to ALA-PDT and TNBC cells with the lowest PpIX level were resistant to PDT. Treatment of TNBC cells with ABCG2 transporter inhibitor Ko143 significantly increased ALA-PpIX fluorescence, enhanced PpIX mitochondrial accumulation and sensitized cancer cells to ALA-PDT. Ko143 treatment had little effect on PpIX production and ALA-PDT in normal and ER- or HER2-positive cells. These results demonstrate that enhanced ABCG2 activity renders TNBC cell resistance to ALA-PDT and inhibiting ABCG2 transporter is a promising approach for targeting TNBC with ALA-based modality.

21 March 2015 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
PDF file
XYXue Yang
Xue Yang
WLWeihua Li
Weihua Li
PPPratheeba Palasuberniam
Pratheeba Palasuberniam
KMKenneth A. Myers
Kenneth A. Myers
CWChenguang Wang
Chenguang Wang
BCBin Chen
Bin Chen

21 April 2023 in Bioengineering
Verified
Journal Article
Open access
PDF file
RHRichard Howley
Richard Howley
SCSharayu Chandratre
Sharayu Chandratre
BCBin Chen
Bin Chen
5-Aminolevulinic acid (ALA) is a naturally occurring amino acid synthesized in all nucleated mammalian cells. As a porphyrin precursor, ALA is metabolized in the heme biosynthetic pathway to produce protoporphyrin IX (PpIX), a fluorophore and photosensitizing agent. ALA administered exogenously bypasses the rate-limit step in the pathway, resulting in PpIX accumulation in tumor tissues. Such tumor-selective PpIX disposition following ALA administration has been exploited for tumor fluorescence diagnosis and photodynamic therapy (PDT) with much success. Five ALA-based drugs have now received worldwide approval and are being used for managing very common human (pre)cancerous diseases such as actinic keratosis and basal cell carcinoma or guiding the surgery of bladder cancer and high-grade gliomas, making it the most successful drug discovery and development endeavor in PDT and photodiagnosis. The potential of ALA-induced PpIX as a fluorescent theranostic agent is, however, yet to be fully fulfilled. In this review, we would like to describe the heme biosynthesis pathway in which PpIX is produced from ALA and its derivatives, summarize current clinical applications of ALA-based drugs, and discuss strategies for enhancing ALA-induced PpIX fluorescence and PDT response. Our goal is two-fold: to highlight the successes of ALA-based drugs in clinical practice, and to stimulate the multidisciplinary collaboration that has brought the current success and will continue to usher in more landmark advances.

5 April 2022 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MMMatthew Mansi
Matthew Mansi
RHRichard Howley
Richard Howley
SCSharayu Chandratre
Sharayu Chandratre
BCBin Chen
Bin Chen

17 October 2023 in Biochemical Pharmacology
Verified
Journal Article
Closed access
SCSharayu Chandratre
Sharayu Chandratre
JOJordyn Olsen
Jordyn Olsen
RHRichard Howley
Richard Howley
BCBin Chen
Bin Chen